Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, July 1999, p. 1693-1699, Vol. 43, No. 7
The R. W. Johnson Pharmaceutical
Research Institute, Raritan, New Jersey 08869
Received 23 December 1998/Returned for modification 14 April
1999/Accepted 10 May 1999
Many pathogenic bacteria utilize two-component systems consisting
of a histidine protein kinase (HPK) and a response regulator (RR) for
signal transduction. During the search for novel inhibitors, several
chemical series, including benzoxazines, benzimidazoles, bis-phenols,
cyclohexenes, trityls, and salicylanilides, were identified that
inhibited the purified HPK-RR pairs KinA-Spo0F and
NRII-NRI, with 50% inhibitory concentrations
(IC50s) ranging from 1.9 to >500 µM and MICs ranging
from 0.5 to >16 µg/ml for gram-positive bacteria. However,
additional observations suggested that mechanisms other than HPK
inhibition might contribute to antibacterial activity. In the present
work, representative compounds from the six different series of
inhibitors were analyzed for their effects on membrane integrity and
macromolecular synthesis. At 4× MIC, 17 of 24 compounds compromised
the integrity of the bacterial cell membrane within 10 min, as measured
by uptake of propidium iodide. In this set, compounds with lower
IC50s tended to cause greater membrane disruption. Eleven
of 12 compounds inhibited cellular incorporation of radiolabeled
thymidine and uridine >97% in 5 min and amino acids >80% in 15 min.
The HPK inhibitor that allowed >25% precursor incorporation had no
measurable MIC (>16 µg/ml). Fifteen of 24 compounds also caused
hemolysis of equine erythrocytes. Thus, the antibacterial HPK
inhibitors caused a rapid decrease in cellular incorporation of RNA,
DNA, and protein precursors, possibly as a result of the concomitant
disruption of the cytoplasmic membrane. Bacterial killing by these HPK
inhibitors may therefore be due to multiple mechanisms, independent of
HPK inhibition.
Two-component signal transduction
systems (TCS) are regulatory mechanisms ubiquitous among bacteria
(36, 44) and often control the expression of virulence
traits (10, 18, 19). In addition, TCS are associated with
regulation of resistance mechanisms for At least five features have made TCS attractive targets for the
development of novel antimicrobial agents: (i) they are present in most
bacterial species (11, 36); (ii) most bacteria contain multiple TCS, each generally controlling different functions (32, 33, 48); (iii) HPKs and also RRs have a high degree of homology around the active sites (36, 48); (iv) they have not been found in either invertebrates or vertebrates (2, 7, 24); and
(v) X-ray crystallographic structures exist for several RRs, including
CheY (43) and Spo0F (27), and for the HPKs ArcB (20) and CheA (51). These features suggested that
an inhibitor of multiple TCS of a bacterial pathogen could be
identified that did not affect cellular functions of its eukaryotic
host. An agent with such properties would be expected to interfere with
the adaptive responses of the pathogen, attenuate its virulence, and
possibly inhibit its growth.
Our group (16, 17, 22, 23, 26, 46, 49) and others (9,
40) have recently described several chemical series of compounds
displaying inhibitory activity against TCS. In our laboratory, soluble
KinA-Spo0F was chosen as the prototype TCS and used in the primary
screening assay. A second soluble TCS, NRII-NRI, was used in secondary assays. Several
series of compounds, including benzoxazines (23),
benzimidazoles (16), bis-phenols (49),
cyclohexenes (22, 46), trityls (5), and
salicylanilides (17, 26), inhibited the purified HPK-RR pair
KinA-Spo0F with 50% inhibitory concentrations (IC50s)
ranging from 1.9 to >500 µM and MICs ranging from 0.5 to >16
µg/ml for gram-positive bacteria. Compounds such as RWJ-49815 and
selected salicylanilides and cyclohexenes were furthermore shown to
inhibit TCS in bacterial cells at concentrations insufficient to
inhibit growth (5, 26, 46). Though this suggested that
inhibition of the TCS preceded growth inhibition, it did not
necessarily imply a causal relationship. Many of these compounds were
hydrophobic, displayed acute in vivo toxicity in mice (30),
and did not exhibit a strong correlation between HPK IC50s
and MICs, thus suggesting that mechanisms other than HPK inhibition
might also be operative for growth inhibition.
In the present work we have examined the ability of selected TCS
inhibitors to interfere with the integrity of cell membranes from
Staphylococcus aureus and mammalian blood cells as well as with the biosynthesis of various macromolecules. Our results suggest that the characterized compounds exhibit several modes of action and
that their effects on bacterial growth may occur through mechanisms other than TCS inhibition.
(This work was presented in part at the 38th Interscience Conference on
Antimicrobial Agents and Chemotherapy, San Diego, Calif., 1998.)
Reagents.
Levofloxacin was provided by Daiichi Seiyaku Co.,
Ltd., Kyoto, Japan. The bis-phenol P-3 (CAS 128-94-9) was purchased
from Aldrich (Milwaukee, Wis.). Polymyxin B, gramicidin S, rifampin, and tetracycline were purchased from Sigma Chemical Company (St. Louis,
Mo.). Cation-adjusted Mueller-Hinton broth (CAMHB) and Trypticase soy
agar were purchased from BBL (Cockeysville, Md.). Bacto Peptone was
purchased from Difco (Detroit, Mich.). All other exploratory compounds
(Fig. 1) were synthesized in the laboratories at The R. W. Johnson
Pharmaceutical Research Institute (Raritan, N.J.).
Bacterial strains.
S. aureus ATCC 29213 was used for
all assays.
Enzyme purification.
KinA was purified by ion exchange and
affinity column chromatography from lysates of Escherichia
coli carrying recombinant plasmid pJM8118, in which the
kinA gene is under the control of the inducible
tac promoter, as previously described (37).
His6-Spo0F was purified by affinity chromatography from a
lysate of E. coli BL21(DE3) containing an
NdeB-BamHI insert of a PCR amplicon of the
spo0F gene of Bacillus subtilis cloned into the
pET16b vector (Novagen, Madison, Wis.), which was obtained from J. Hoch. His6-NRI was expressed from the pPRO-EX-1
vector in E. coli DH5 Enzyme inhibition assays.
KinA-Spo0F and
NRII-NRI autophosphorylation and
phosphotransferase activities were analyzed by a gel-based assay
(5). IC50s were determined graphically after
scanning the gel with the Bio-Rad GS-250 phosphoimager (Hercules,
Calif.). The IC50 was defined as the concentration of
compound that inhibited KinA or NRII phosphorylation by
50%.
MIC.
Broth microdilution MIC determinations were performed
according to National Committee for Clinical Laboratory Standards
methods (34). The MIC was defined as the lowest
concentration of compound or drug that inhibited visible growth.
Membrane damage.
The BacLight kit from Molecular Probes,
Inc. (Eugene, Oreg.) was used to assess membrane damage. In this assay,
the SYTO-9 and propidium iodide stains compete for binding to the
bacterial nucleic acid. SYTO-9 labels cells with both damaged and
intact membranes, whereas propidium iodide penetrates only cells with damaged membranes. S. aureus was grown overnight in CAMHB at
37°C with aeration (200 rpm). The culture was diluted 1:40 in fresh CAMHB and grown to an optical density at 600 nm (OD600) of
0.5 to 0.6. The bacterial suspension was centrifuged at
10,000 × g for 15 min, and the cell pellet was washed
once in filter-sterilized distilled water. The cell pellet was
resuspended to 1/10 of the original volume and then diluted 1:20 into
either water or water containing test compounds at 4× MIC. Bacteria
and compounds were incubated at room temperature (~23°C) on a tube
rocker for 10 min. At the end of the incubation period, a sample was
removed for CFU determination, and the remaining suspension was
centrifuged at 10,000 × g for 10 min, washed once in
water, and resuspended to an OD670 of 0.325. A volume of
100 µl of the bacterial suspension was removed and added to a 96-well
Cytofluor plate (PerSeptive Biosystems). An equal volume of the
BacLight reagent was then added to each well, and the plates were
incubated in the dark for 15 min at room temperature. At the end of the
incubation period, green fluorescence (SYTO-9) was read at 530 nm, and
red fluorescence (propidium iodide) was read at 645 nm with a
PerSeptive Biosystems Cytofluor 2350 (excitation wavelength, 485 nm).
The ratio of green to red fluorescence was normalized to the untreated
control and expressed as a percentage of the control.
Bacterial viability.
Following the 10-min exposure to the
compound, a sample was removed and inoculated into chilled 0.1%
peptone. The culture was serially diluted and plated in Trypticase soy
agar for CFU determination. Agar plates were incubated at 37°C for 18 to 20 h. Bacterial colonies were counted, and the log decrease in
CFU/milliliter compared to the untreated control was calculated.
Macromolecular synthesis.
Macromolecular synthesis in
S. aureus was evaluated by measuring the incorporation of
the appropriate radiolabeled precursors into bacteria prior to
treatment with trichloroacetic acid (TCA) (41). The inoculum
was prepared by incubating S. aureus bacteria overnight at
35°C in CAMHB with shaking at 200 rpm. The culture was then diluted
1:50 in fresh prewarmed CAMHB and incubated for 1 h. Broth was
removed from the bacteria by centrifugation for 15 min at
3,500 × g. The S. aureus pellet was
suspended in M9 minimal medium and adjusted to an OD450 of
0.2. The bacterial cells were then exposed to the test compounds and
control antibacterials at 4× MIC for 10 min. A nonspecific binding
control, containing medium alone, was also prepared. DNA synthesis was
measured by labeling 1 ml of culture with 1 µl of
[3H]thymidine (76 Ci/mmol at 0.1 µCi/ml, TRK686;
Amersham) for 5 min. RNA synthesis was determined by adding 5 µl of
[3H]uridine (40 Ci/mmol at 0.5 µCi/ml, TRK410;
Amersham) to 1 ml of S. aureus bacteria for 5 min. Protein
synthesis was measured by labeling 1 ml of S. aureus
bacteria with 100 µl of 3H-amino acid mixture (40 Ci/mmol
at 10 µCi/ml, TRK410; Amersham) for 15 min. Following the
radiolabeling, 1 ml of cold 10% TCA was added to all samples; for
amino acid studies, unlabeled amino acids (0.5 mg/ml) were added to
each amino acid-labeled sample simultaneously with the TCA. All samples
were filtered through a glass microfiber filter (GF/A, 25-mm; Whatman)
by using a Millipore 12 sample manifold. Each filter was first washed
with 5 ml of ice-cold 10% TCA, followed by 5 ml of cold distilled
water. The dried filters were counted in a liquid scintillation counter
(LS 6000TA; Beckman).
Erythrocyte hemolysis.
Hemolytic activity of the compounds
was determined by using equine erythrocytes (BBL). The erythrocytes
were washed three times in 10 mM Tris-HCl (pH 7.4) buffer containing
0.9% NaCl and resuspended to 1% immediately prior to assay (8,
31). A volume of 200 µl of the cell suspension was added to
1,300 µl of buffer containing the compound. Cells were added to
buffer alone or to 0.5% NH4OH for the zero and 100%
hemolysis controls, respectively. The cell suspension was incubated 10 min at room temperature on a tube rocker and centrifuged at
1,300 × g for 5 min. Hemoglobin release from the cells
was determined by measuring A540.
Compound selection.
Benzimidazoles, benzoxazines, bis-phenols,
cyclohexenes, trityls, and salicylanilides included in the TCS
screening program were synthesized specifically for this purpose.
Biochemical screening against the KinA-Spo0F enzymes yielded compounds
displaying a broad range of IC50s (2 to >500 µM). MICs
were then determined for the most-active inhibitors, as well as for
selected, less-active compounds, in order to establish
structure-activity relationships.
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Multiple Mechanisms of Action for Inhibitors of
Histidine Protein Kinases from Bacterial Two-Component
Systems
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
-lactams (3, 14),
polymyxin B (13), tetracycline (42), and
vancomycin (4). In their simplest form they consist of a
histidine protein kinase (HPK) and a response regulator (RR) (36).
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
(45). Both
histidine-tagged proteins were purified by using nickel resin affinity
chromatography. The NRII protein was purified from a lysate
of E. coli RB9132 provided by J. Hoch containing the
glnL gene expressed by the pJLA501 vector as previously
described by Ninfa et al. (35). NRII was
purified by affinity and gel filtration chromatography.
![]()
RESULTS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

View larger version (20K):
[in a new window]
FIG. 1.
Structures of various chemical classes of TCS
inhibitors. Previous designations for selected compounds are RWJ-49815
for T-1 (5), 9 for S-1, 14 for S-2, 1 for S-3, and 23 for
S-4 (26).
Enzyme inhibition assays.
Kinase inhibitory activity as
measured by IC50s is shown in Table
1 (22, 23, 26, 49). Inhibition
by compounds in the benzimidazole (B-), trityl (T-), and benzoxazine
(X-) classes was comparable for both enzymes. For most of the compounds
in the bis-phenol and salicylanilide classes (P- and S-), there was little correlation between the KinA-Spo0F and
NRII-NRI results; an IC50 of <100
µM against KinA-Spo0F was not predictive of equivalent potency
against NRII-NRI.
|
Antibacterial activity.
Susceptibility of S. aureus
to the test compounds and selected reference agents is shown in Table
1. With the exception of the benzimidazoles and trityls, there was no
strong correlation between antibacterial activity and enzyme
inhibition. For the benzimidazoles, compounds with IC50s of
<100 µM against KinA had MICs of 2 µg/ml, whereas B-4 with
IC50s
230 µM had a MIC of 8 µg/ml. In the trityl
series, T-1 and T-2 with IC50s
20 µM also demonstrated
comparable antimicrobial activity against S. aureus, with
MICs of 2 µg/ml. For the cyclohexenes, the NRII
IC50s had a positive correlation with antibacterial
activity; however, there was no correlation with KinA inhibition. The
MICs of compounds B-4, S-2, S-4, and P-4, with structural similarities
to other members of their class, ranged from 2 to 8 µg/ml despite the
lack of measurable TCS inhibitory activity.
Membrane damage.
Bacterial membrane damage was examined by
using the BacLight assay. As the BacLight data in Table 1 indicate,
71% (17 of 24) of the compounds
primarily in the benzimidazole,
bis-phenol, trityl, and benzoxazine classes
altered the permeability
of the membrane, resulting in <40% of control value. C-1 was the only cyclohexene that damaged the bacterial membrane within 10 min. As a
class, the salicylanilides displayed moderate membrane effects, though
these compounds had good antibacterial activity. Gramicidin S is a
compound that depolarizes the membrane by forming channels (25), and polymyxin B is a cationic detergent that binds
lipoteichoic acid and may induce autolysis (12, 39). As
expected among the controls, gramicidin S and polymyxin B severely
compromised the bacterial cell membrane. Levofloxacin, tetracycline,
and rifampin had little effect on membrane integrity.
Bacterial viability.
Because bacterial membrane damage is not
necessarily a lethal event, the ability of compound-exposed cells to
form colonies on solid agar medium was determined. In contrast to the
BacLight data that indicated membrane damage, only 6 of 24 compounds
appreciably reduced the number of CFU compared to the control
(
0.9-log reduction in CFU/ml) during the 10-min exposure. The
cyclohexenes showed a positive correlation between the BacLight data
and the reduction in CFU. The benzimidazole B-1, the trityl T-1, and
the benzoxazine X-2 significantly damaged the membrane at 10 min
(
90% permeability compared to the no-drug control) yet showed less
than a 1-log drop in CFU/ml. By 60 min, however, there was a 2- to
6-log drop in CFU/ml for these compounds without further membrane
damage (data not shown). Thus, the observable change in membrane damage as detected by the BacLight assay occurs rapidly and precedes the
decrease in viability. Note that these are results of a short-term exposure (10 min) to compound in water, rather than the 16 to 20 h
of exposure in medium routinely used in MIC determinations.
Macromolecular synthesis. Twelve synthetic compounds were tested in the three macromolecular synthesis assays to evaluate [3H]thymidine, [3H]uridine, and 3H-amino acid mixture incorporation into DNA, RNA, and protein, respectively, after short exposure to the TCS inhibitors. The results of these assays are summarized in Fig. 2. Five antibacterial agents with various mechanisms of action were tested as controls. All of the compounds tested, except P-3, inhibited incorporation of all three macromolecular precursors. The bis-phenol P-3 inhibited thymidine and uridine incorporation but had minor effects on amino acid incorporation.
|
Hemolysis. Eukaryotic membrane damage by these compounds was assessed by examining hemolysis of equine erythrocytes. Fifteen of 24 (63%) compounds tested lysed erythrocytes (greater than 10% of the control). Background hemolysis of the untreated control erythrocytes was 2%. The cyclohexene and trityl series showed nearly complete hemolysis of the cells, as shown in Table 1. The bis-phenols were not hemolytic, whereas both the benzimidazoles and benzoxazines caused varying degrees of hemolytic activity. Only one salicylanilide, S-4, caused hemolysis (22%). Gramicidin S was the only reference compound to cause appreciable hemolysis (18% of the control). Hemolytic activity did not correlate with bacterial membrane damage.
| |
DISCUSSION |
|---|
|
|
|---|
New analogs of existing antibiotics generally result in therapeutic agents whose utility to treat infectious disease is compromised by emergent drug resistance. Agents with new mechanisms of action are needed to provide a longer-term solution to this problem. Inhibition of the bacterial two-component signal transduction systems has been an appealing solution to the problem of antimicrobial drug resistance (5, 40). Two-component systems are ubiquitous among bacteria and are multiply present in each species where they regulate adaptive responses, including the regulation of virulence traits (10, 18, 19) and resistance mechanisms (3, 4, 13, 14, 42). Furthermore, they have in common structural motifs not found among higher eukaryotes, thus suggesting that agents capable of inhibiting them could have the specificity and selectivity inherent to safe and effective antimicrobial agents. However, as shown above, these expectations were not met by the six structural classes of inhibitors examined in our studies.
Twenty-three of the 24 compounds evaluated as putative HPK inhibitors either appreciably affected the membrane integrity of S. aureus or caused hemolysis of equine erythrocytes. The IC50s of the remaining compound, the bis-phenol P-4 which caused appreciably less damage to the S. aureus membrane, were >500 µM in both enzyme assays. Furthermore, for a subset of the 24 compounds, bacterial viability was affected within a 10-min exposure to compound. In addition, 11 of 12 compounds reduced the incorporation of thymidine, uridine, and amino acids into macromolecules by more than 80%. This result strongly suggests that the observed reductions resulted from a general effect upon either uptake or intracellular retention of the precursors and not on each of the individual macromolecular biosynthetic processes per se. Indeed, the membrane effects are very similar to those seen with some peptide antimicrobial agents. For example, as seen in our studies as well as in previous work (21), the cyclic peptide gramicidin S disrupts cell membranes in gram-positive bacteria, and the cyclic peptide daptomycin simultaneously inhibits the biosynthesis of RNA, DNA, peptidoglycan, and lipid (6). Daptomycin also inhibits amino acid transport by disrupting the membrane potential (1). The 11 inhibitors of macromolecular synthesis in this study may be acting in a similar manner.
The data suggest that certain structural features may be affecting membrane integrity. All of the examined compounds appeared to alter uptake of small molecules, such as propidium iodide, and macromolecular synthesis precursors. In the trityl series, replacement of the guanidinium by a carboxyl reduced the effect on the bacterial membrane, whereas extension of the alkanyl of T-1 and T-2 resulted in compounds causing increased membrane alteration. For the bis-phenols, addition of the hydrophobic trichloromethyl group (P-1) drastically increased bactericidal activity. In contrast, the addition of amino groups on P-3 reduced both the effects on membrane integrity and bactericidal activity. Similarly, for the cyclohexene C-1, the substitution of a Cl for H and guanidine for amine reduced bacterial membrane integrity and increased bactericidal activity. However, all compounds in this series were hemolytic. For the benzimidazoles, compounds containing the di-t-butylphenol moiety (B-1 to B-3) appeared to be associated with serious membrane damage. Replacement of the carboxyl (B-3) or aminoalkylamide (B-2) moiety with the amidine functionality (B-1) reduced bactericidal activity and hemolysis. In the benzoxazine series, the levels of bactericidal activity and bacterial membrane damage were fairly consistent, despite significant variation in structure (X-1 through X-4).
Clearly, the salicylanilide class of compounds behaved differently from the other inhibitors. This class contained the most-potent antibacterial agents; yet the enzymatic inhibitory activity was inconsistent throughout the series, with S-3 (closantel) being the most active. There was no correlation between enzymatic activity and membrane damage; all compounds caused moderate membrane damage (35 to 80% of the control). Prolonged exposure of S-1 to the cells (60 min) did not increase membrane damage as measured by the BacLight reagents, and it did not reduce the CFU/milliliter compared to the control (data not shown), consistent with the report of salicylanilide antibacterial agents as static (15). Closantel (S-3) is a hydrogen ionophore and is known to uncouple oxidative phosphorylation in mitochondria (28, 47). Both salicylanilides and halogenated benzimidazoles are known to act as uncouplers of oxidative phosphorylation, though they differ in their specific mechanisms of action (52). Furthermore, whereas salicylanilides act as bacteriostatic agents, benzimidazoles are often bactericidal (see especially B-2 and B-3). Therefore, it is likely that salicylanilides and benzimidazoles have multiple mechanisms of action and that they differ in their primary targets.
It is clear from the results presented here that compounds differed greatly among themselves in their patterns of effects on S. aureus membranes and horse erythrocyte membranes and in their short-term bactericidal effects. These differences were noticeable even when compounds of the same series were being compared. Since these effects are operative on both prokaryotic and eukaryotic membranes, they cannot be the consequence of the selective activity of these compounds on bacterial TCS. Hence, these compounds have multiple mechanisms of action, since they also must be acting upon targets other than bacterial TCS.
The chemical series used for our program originated either from similar structures in the literature (9, 40) or from computer modelling with the X-ray crystallographic structures for CheY (43) and Spo0F (27). Given that KinA and Spo0F were both soluble enzymes, it was unexpected that our selection yielded primarily compounds that had poor specificity and that behaved as membrane disrupters. However, knowing that some of the active compounds displayed detergent-like features, we investigated the possibility that lipophilic membrane disrupters may act as KinA-Spo0F inhibitors. Among 45 commercially available detergents representing a variety of families of structures, only 12 showed KinA-Spo0F inhibitory activity at concentrations below 500 µM. The more-inhibitory detergents, whose IC50s were between 6 and 18 µM, contained C14 to C16 aliphatic chains with quaternary ammonium groups. Though aliphatic chain length was important, the charged groups were also important. Thus, whereas the IC50 of sodium dodecyl sulfate was 78 µM, dodecyl quaternary ammonium salts, as well as detergents such as polyethylene glycol ethers, taurocholic acid, Pluronic F-127, okadaic acid, N-N-bis[3-(D-gluconamido)propyl]cholamide, laudanosine methiodide, and benzyldimethylphenylammonium chloride, did not inhibit TCS at concentrations of 500 µM (23a). Therefore, inhibition of KinA-Spo0F, even by detergents, showed specificity.
Our results do not necessarily invalidate the value of bacterial TCS as novel targets for antimicrobial agents. However, they emphasize potential problems that may be inherent to the inhibitors identified through the use of these biochemical assays. Thus, notwithstanding our initial expectations, searching for agents that simultaneously inhibit multiple TCS and show good antibacterial activity may yield compounds with broad specificity and poor selectivity. This problem may now be circumvented by focusing on inhibitors for only those particular TCS that may be essential for pathogenic bacteria. Inhibition of these individual systems would then result in growth inhibition or bacterial killing. Such systems have been recently identified (29, 38) and may represent an opportunity to exploit TCS as novel targets in a more selective approach.
| |
ACKNOWLEDGMENTS |
|---|
We thank Dennis Hlasta and Mark Macielag for their contributions to the HPK project and their critical assessment of the manuscript; Barbara Foleno and Ellyn Wira for performing susceptibility testing; and Thurman Dow, Jeffrey Fernandez, Michael Loeloff, and Glenda Webb for assistance with some of the biochemical assays.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: The R. W. Johnson Pharmaceutical Research Institute, 1000 Route 202, Raritan, NJ 08869. Phone: (908) 704-4871. Fax: (908) 526-3047. E-mail: jhilliar{at}prius.jnj.com.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Alborn, W. E., Jr.,
N. E. Allen, and D. A. Preston.
1991.
Daptomycin disrupts membrane potential in growing Staphylococcus aureus.
Antimicrob. Agents Chemother.
35:2282-2287 |
| 2. | Alex, L. A., and M. I. Simon. 1994. Protein histidine kinases and signal transduction in prokaryotes and eukaryotes. Trends Genet. 10:133-138[Medline]. |
| 3. |
Alksne, L., and B. A. Rasmussen.
1997.
Expression of the AsbA1, OXA-12, and AsbM1 -lactamases in Aeromonas jandaei AER 14 is coordinated by a two-component regulon.
J. Bacteriol.
179:2006-2013 |
| 4. |
Arthur, M.,
C. Molinas, and P. Courvalin.
1992.
The VanS-VanR two-component regulatory system controls synthesis of depsipeptide peptidoglycan precursors in Enterococcus faecium BM4147.
J. Bacteriol.
174:2582-2591 |
| 5. |
Barrett, J. F.,
R. M. Goldschmidt,
L. E. Lawrence,
B. Foleno,
R. Chen,
J. P. Demers,
S. Johnson,
R. Kanojia,
J. Fernandez,
J. Bernstein,
L. Licata,
A. Donetz,
S. Huang,
D. J. Hlasta,
M. J. Macielag,
K. Ohemeng,
R. Frechette,
M. B. Frosco,
D. H. Klaubert,
J. M. Whiteley,
L. Wang, and J. A. Hoch.
1998.
Antibacterial agents that inhibit two-component signal transduction systems.
Proc. Natl. Acad. Sci. USA
95:5317-5322 |
| 6. |
Canepari, P.,
M. Boaretti,
M. Del Mar Lleo, and G. Satta.
1990.
Lipoteichoic acid as a new target for activity of antibiotics: mode of action of daptomycin (LY146032).
Antimicrob. Agents Chemother.
34:1220-1226 |
| 7. |
Chang, C., and R. C. Stewart.
1998.
The two-component system. Regulation of diverse signaling pathways in prokaryotes and eukaryotes.
Plant Physiol.
117:723-731 |
| 8. | Dathe, M., M. Schumann, T. Wieprecht, A. Winkler, M. Beyerman, E. Krause, O. Matsuzaki, and M. Bienert. 1996. Peptide helicity and membrane surface charge modulate the balance of electrostatic and hydrophobic interactions with lipid bilayers and biological membranes. Biochemistry 35:12612-12622[Medline]. |
| 9. | Domagala, J. M., D. Alessi, S. Gracheck, L. Huang, M. Huband, E. Olson, M. Shapiro, R. Singht, Y. Song, R. VanBogelen, and D. Vot. 1997. Bacterial two-component signaling as a therapeutic target in drug design: inhibition of NRII by diphenolic methanes, abstr. 44. In Program and abstracts of the 29th Central Regional Meeting of the American Chemical Society, Midland, Mich.. |
| 10. | Dziejman, M., and J. J. Mekalanos. 1995. Two-component signal transduction and its role in the expression of bacterial virulence factors, p. 305-317. In J. A. Hoch, and T. J. Silhavy (ed.), Two-component signal transduction. ASM Press, Washington, D.C. |
| 11. | Egger, L. A., H. Park, and M. Inouye. 1997. Signal transduction via the histidyl-aspartyl phosphorelay. Genes Cells 2:167-184[Abstract]. |
| 12. | Ginsburg, I., M. Lahav, and P. Giesbrecht. 1982. Effect of leukocyte hydrolases on bacteria. XVI. Activation by leukocyte factors and cationic substances of autolytic enzymes in Staphylococcus aureus: modulation by anioic polyelectrolytes in relation to survival of bacteria in inflammatory exudates. Inflammation 6:269-284[Medline]. |
| 13. |
Groisman, E. A.,
J. Kayser, and F. C. Soncini.
1997.
Regulation of polymyxin resistance and adaptation to low-Mg2+ environments.
J. Bacteriol.
179:7040-7045 |
| 14. | Guenzi, E., A. M. Gasc, M. A. Sicard, and R. Hakenbeck. 1994. A two-component signal-transducing system is involved in competence and penicillin susceptibility in laboratory mutants of Streptococcus pneumoniae. Mol. Microbiol. 12:505-515[Medline]. |
| 15. | Hamilton, W. A. 1968. Mechanism of the bacteriostatic action of tetrachlorosalicylanilide. Membrane-active antibacterial compound. J. Gen. Microbiol. 50:441-458[Medline]. |
| 16. | Hilliard, J. J., L. Licata, R. Goldschmidt, E. Z. Baum, M. Macielag, D. J. Hlasta, and K. Bush. 1998. Multiple mechanisms of action for inhibitors of histidine protein kinase from bacterial two-component systems, abstr. F-161, p. 273. In Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C. |
| 17. | Hlasta, D. J., J. P. Demers, B. D. Foleno, S. A. Fraga-Spano, J. Guan, J. J. Hilliard, M. J. Macielag, K. A. Ohemeng, C. M. Sheppard, Z. Sui, G. C. Webb, M. A. Weidner-Wells, H. Werblood, and J. F. Barrett. 1998. Novel inhibitors of bacterial two-component systems with gram positive antibacterial activity: pharmacophore identification based on the screening hit closantel. Bioorg. Med. Chem. Lett. 8:1923-1928. [Medline] |
| 18. | Jones, A. L., D. DeShazer, and D. E. Woods. 1997. Identification and characterization of a two-component regulatory system involved in invasion of eukaryotic cells and heavy-metal resistance in Burkholderia pseudomallei. Infect. Immun. 65:4972-4977[Abstract]. |
| 19. |
Jungnitz, H.,
N. P. West,
M. J. Walker,
G. S. Chhatwal, and C. A. Guzmán.
1998.
A second two-component regulatory system of Bordetella bronchiseptica required for bacterial resistance to oxidative stress, production of acid phosphatase, and in vivo persistence.
Infect. Immun.
66:4640-4650 |
| 20. | Kato, M., T. Mizuno, T. Shimizu, and T. Hakoshima. 1997. Insights into multistep phosphorelay from the crystal structure of the C-terminal HPt domain of ArcB. Cell 88:717-723[Medline]. |
| 21. | Katsu, T., M. Kuroko, T. Morikawa, K. Sanchika, Y. Fujita, H. Yamamura, and M. Uda. 1989. Mechanism of membrane damage induced by the amphipathic peptides gramicidin S and melittin. Biochim. Biophys. Acta 983:135-141[Medline]. |
| 22. | Lawrence, L., S. Huang, B. Foleno, R. Chen, and J. F. Barrett. 1997. In vitro activity and mechanism of action of a series of novel two-component system inhibitors, abstr. F-225, p. 184. In Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C. |
| 23. | Licata, L., J. L. Melton, J. A. Fernandez, R. F. Frechette, M. Beach, G. Webb, L. E. Lawrence, J. F. Barrett, and M. B. Frosco. 1997. In vitro characterization of a novel class of antibacterial agents that inhibit bacterial two-component systems, abstr. F-226, p. 184. In Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C. |
| 23a. | Loeloff, M. Unpublished results. |
| 24. | Loomis, W. F., G. Shaulsky, and N. Wang. 1997. Histidine kinases in signal transduction pathways of eukaryotes. J. Cell Sci. 110:1141-1145[Abstract]. |
| 25. | López-Amorós, R., J. Comas, and J. Vives-Rego. 1995. Flow cytometric assessment of Escherichia coli and Salmonella typhimurium starvation-survival in seawater using rhodamine 123, propidium iodide, and oxonol. Appl. Environ. Microbiol. 61:2521-2526[Abstract]. |
| 26. | Macielag, M. J., J. P. Demers, S. A. Fraga-Spano, D. J. Hlasta, S. G. Johnson, R. M. Kanojia, R. K. Russell, Z. Sui, M. A. Weidner-Wells, H. Werblood, B. D. Foleno, R. M. Goldschmidt, M. J. Loeloff, G. C. Webb, and J. F. Barrett. 1998. Substituted salicylanilides as inhibitors of two-component regulatory systems in bacteria. J. Med. Chem. 41:2939-2945[Medline]. |
| 27. | Madhusudan, J., Zapf, J. M. Whiteley, J. A. Hoch, N. H. Xuong, and K. I. Varughese. 1996. Crystal structure of a phosphatase-resistant mutant of sporulation response regulator Spo0F from Bacillus subtilis. Structure 4:679-690[Medline]. |
| 28. | Maes, L. 1988. Flukicidal action of closantel against immature and mature Fasciola hepatica in experimentally infected rats and sheep. Res. Vet. Sci. 44:229-232[Medline]. |
| 29. | Martin, P. K., T. Li, D. Sun, D. P. Biek, and M. B. Schmid. 1998. Genetic evidence for the essential nature of an HK/RR signal transduction circuit in Staphylococcus aureus, abstr. B-46, p. 63. In Abstracts of the 98th General Meeting of the American Society for Microbiology. American Society for Microbiology, Washington, D.C. |
| 30. | Melton, J. L., J. A. Fernandez, R. F. Frechette, M. J. Beach, L. Licata, D. B. Mehta, J. F. Barrett, and M. B. Frosco. 1997. In vivo activity of a novel series of antibacterial agents that inhibit the bacterial two-component signal transduction system, abstr. F-229, p. 185. In Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C. |
| 31. | Miyoshi, S., K. Sashara, S. Akamatsu, H. M. Rahman, T. Katsu, K. Tomochika, and S. Shinoda. 1997. Purification and characterization of a hemolysin produced by Vibrio mimicus. Infect. Immun. 65:1830-1835[Abstract]. |
| 32. | Mizuno, T. 1997. Compilation of all genes encoding two-component phosphotransfer signal transducers in the genome of Escherichia coli. DNA Res. 4:161-168[Abstract]. |
| 33. | Mizuno, T., T. Kaneko, and S. Tabata. 1996. Compilation of all genes encoding bacterial two-component signal transducers in the genome of the cyanobacterium, Synechocystis sp. strain PCC 6803. DNA Res. 3:407-414[Abstract]. |
| 34. | National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Villanova, Pa. |
| 35. |
Ninfa, E. G.,
M. R. Atkinson,
E. S. Kamberov, and A. J. Ninfa.
1993.
Mechanism of autophosphorylation of Escherichia coli nitrogen regulator II (NRII or NtrB): trans-phosphorylation between subunits.
J. Bacteriol.
175:7024-7032 |
| 36. | Parkinson, J. S., and E. C. Kofoid. 1992. Communication modules in bacterial signaling proteins. Annu. Rev. Genet. 26:71-112[Medline]. |
| 37. |
Perego, M.,
S. P. Cole,
D. Burbulys,
K. Trach, and J. A. Hoch.
1989.
Characterization of the gene for a protein kinase which phosphorylates the sporulation-regulatory proteins Spo0A and Spo0F of Bacillus subtilis.
J. Bacteriol.
171:6187-6196 |
| 38. |
Quon, K. C.,
B. Yang,
I. J. Domian,
L. Shapiro, and G. T. Marczynski.
1998.
Negative control of bacterial DNA replication by a cell cycle regulatory protein that binds at the chromosome origin.
Proc. Natl. Acad. Sci. USA
95:120-125 |
| 39. |
Renzi, P. M., and C.-H. Lee.
1995.
A comparative study of biological activities of lipoteichoic acid and lipopolysaccharide.
J. Endotoxin Res.
2:431-434.
|
| 40. |
Roychoudhury, S.,
N. A. Zielinski,
A. J. Ninfa,
N. E. Allen,
L. N. Jungheim,
T. I. Nicas, and A. M. Chakrabarty.
1993.
Inhibitors of two-component signal transduction systems: inhibition of alginate gene activation in Pseudomonas aeruginosa.
Proc. Natl. Acad. Sci. USA
90:965-969 |
| 41. |
Singh, M. P.,
P. J. Petersen,
N. V. Jacobus,
W. M. Maiese,
M. Greenstein, and D. A. Steinberg.
1994.
Mechanistic studies and biological activity of bioxalomycin 2, a novel antibiotic produced by Streptomyces viridodiastaticus subsp. "litoralis" LL-31F508.
Antimicrob. Agents Chemother.
38:1808-1812 |
| 42. |
Stevens, A. M.,
J. M. Sanders,
N. B. Shoemaker, and A. A. Salyers.
1992.
Genes involved in production of plasmidlike forms by a Bacteroides conjugal chromosomal element share amino acid homology with two-component regulatory systems.
J. Bacteriol.
174:2935-2942 |
| 43. | Stock, A. M., E. Martinez-Hackert, B. F. Rasmussen, A. H. West, J. B. Stock, D. Ringe, and G. A. Petsko. 1993. Structure of the magnesium-bound form of CheY and mechanism of phosphoryl transfer in bacterial chemotaxis. Biochemistry 32:13375-13380[Medline]. |
| 44. |
Stock, J. B.,
A. J. Ninfa, and A. M. Stock.
1989.
Protein phosphorylation and regulation of adaptive responses in bacteria.
Microbiol. Rev.
53:450-490 |
| 45. | Tzeng, Y.-L., and J. A. Hoch. 1997. Molecular recognition in signal transduction: the interaction surfaces of the Spo0F response regulator with its cognate phosphorelay proteins revealed by alanine scanning mutagenesis. J. Mol. Biol. 272:200-212[Medline]. |
| 46. |
Urbanski, M. J.,
M. A. Xiang,
B. D. Foleno,
J. I. Bernstein,
L. Lawrence,
R. M. Goldschmidt,
J. F. Barrett,
R. Frechette, and R. Chen.
1997.
Novel cyclohexene derivatives with histidine protein kinase inhibitory activity potential new antibacterial agents, abstr. MEDI-270.
In
Abstracts of the 214th American Chemical Society National Meeting, Las Vegas, Nev..
|
| 47. | Vanden Bossche, H. 1985. How anthelmintics help us to understand helminths. Parasitology 90:675-685. |
| 48. | Volz, K. 1993. Structural conservation in the CheY superfamily. Biochemistry 32:11741-11753[Medline]. |
| 49. | Webb, G. C., B. L. Podlogar, M. Frosco, B. D. Foleno, K. A. Ohemeng, and J. F. Barrett. 1997. Simple bis-phenols inhibit bacterial two-component phospho-transfer transduction, abstr. F-230, p. 185. In Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C. |
| 50. | Weidner-Wells, M. A., J. Bernstein, R. H. K. Chen, J. P. Demers, B. Foleno, S. A. Fraga-Spano, D. J. Hlasta, S. G. Johnson, R. Kanojia, M. D. Klaubert, H. C. M. Sheppard, and J. F. Barrett. 1997. Triphenylalkyl derivatives as inhibitors of bacterial two-component regulatory systems, abstr. MEDI-148. In Abstracts of the 214th American Chemical Society National Meeting, Las Vegas, Nev.. |
| 51. | Welch, M., N. Chinardet, L. Mourey, C. Birck, and J.-P. Samama. 1998. Structure of the CheY-binding domain of histidine kinase CheA in complex with CheY. Nat. Struct. Biol. 5:25-29[Medline]. |
| 52. | Wilson, D. F., H. P. Ting, and M. S. Koppelman. 1971. Mechanism of action of uncouplers of oxidative phosphorylation. Biochemistry 10:2897-2902[Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |